Evidence map›Paper›PMID 38794277›Full record

ArticlePharmaceutics2024

Organ-on-a-Chip:

Ana Sofia Morais, Maria Mendes, Marta Agostinho Cordeiro, João J Sousa, Alberto Canelas Pais, Silvia M Mihăilă, Carla Vitorino

Abstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ana Sofia MoraisFaculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal.
Maria MendesFaculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0003-3696-4517
Marta Agostinho CordeiroFaculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0001-9644-6282
João J SousaFaculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0001-9718-8035
Alberto Canelas PaisCoimbra Chemistry Centre, Department of Chemistry, University of Coimbra, 3004-535 Coimbra, Portugal.ORCID 0000-0002-6725-6460
Silvia M MihăilăDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3508 TB Utrecht, The Netherlands.
Carla VitorinoFaculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0003-3424-548X

Funding

Fundação para a Ciência e a Tecnologia 10.54499/2022.06174.PTDCFundação para a Ciência e a Tecnologia 10.54499/UIDB/00313/2020Santander Universities 3BBBioprinting
6 · The paper itself

Abstract

This review outlines the evolutionary journey from traditional two-dimensional (2D) cell culture to the revolutionary field of organ-on-a-chip technology. Organ-on-a-chip technology integrates microfluidic systems to mimic the complex physiological environments of human organs, surpassing the limitations of conventional 2D cultures. This evolution has opened new possibilities for understanding cell-cell interactions, cellular responses, drug screening, and disease modeling. However, the design and manufacture of microchips significantly influence their functionality, reliability, and applicability to different biomedical applications. Therefore, it is important to carefully consider design parameters, including the number of channels (single, double, or multi-channels), the channel shape, and the biological context. Simultaneously, the selection of appropriate materials compatible with the cells and fabrication methods optimize the chips' capabilities for specific applications, mitigating some disadvantages associated with these systems. Furthermore, the success of organ-on-a-chip platforms greatly depends on the careful selection and utilization of cell resources. Advances in stem cell technology and tissue engineering have contributed to the availability of diverse cell sources, facilitating the development of more accurate and reliable organ-on-a-chip models. In conclusion, a holistic perspective of in vitro cellular modeling is provided, highlighting the integration of microfluidic technology and meticulous chip design, which play a pivotal role in replicating organ-specific microenvironments. At the same time, the sensible use of cell resources ensures the fidelity and applicability of these innovative platforms in several biomedical applications.

Indexed as

design conceptsmicrofluidic technologyorgan-on-a-chippolydimethylsiloxanestem cell

Identifiers

PMID38794277
PMCPMC11124787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.